CHMP recommends Leo Pharma's tralokinumab for approval in atopic dermatitis

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Leo Pharma's new eczema treatment tralokinumab within the EU. There is hope the drug will take the company to new heights.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Almost five years after acquiring tralokinumab from Astrazeneca, Leo Pharma is at the cusp of getting approval for the drug on the European market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading